Myasthenia Gravis - Market Insight, Epidemiology and Market Forecast 2027



Albany, NY -- (SBWIRE) -- 09/11/2018 -- Myasthenia Gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved in signaling at the neuromuscular junction (NMJ). These proteins include the nicotinic Acetyl Cholinesterase (AChR) or, less frequently, a muscle-specific tyrosine kinase (MuSK). Clinically, MG has 2 major subtypes, primary ocular and generalized. MG often progresses to the more severe and generalized form with weakness of the head, neck, trunk, limb and respiratory muscles. The condition is classified from ocular to incubation stage MG from class I-V as: Class I (ocular), class II, III, IV (including IIa, IIIa, IVa & IIb, IIIb, IVb) as mild, moderate and severe generalized and Class V as intubation stage. The symptoms include breathing difficulties, fatigue, problems chewing and swallowing (choking), facial muscle weakness or paralysis such as eyelid drooping, difficulty talking, difficulty climbing stairs, a drooping head etc. Myasthenia Gravis is considered to be more prevalent in women as compared to men.

According to the report of DelveInsight "Myasthenia Gravis (MG) Market Insights, Epidemiology and Market Forecast-2027", estimates suggest that there were XXXX prevalent cases of Myasthenia Gravis in 2016 in 7MM. These prevalent cases are further expected to increase and reach up to XXXX cases by 2027. United States accounts for the highest prevalent population of Myasthenia Gravis, followed by EU5 and Japan. Among the European countries, Spain had the highest prevalent population of Myasthenia Gravis with XXXX cases, followed by Germany with around XXXX cases in 2016. France had the lowest prevalent pool of Myasthenia Gravis in 2016. Japan had the lowest prevalent population of Myasthenia Gravis in 2016 with XXXX cases. Approximately XX% of patients, autoantibodies, directed against the postsynaptic nicotinic AchR can be detected in the serum and confirm the diagnosis; up to XX% of the remaining MG patients harbor antibodies against MuSK. DelveInsight also estimates that MG is more prevalent in females as compared to males, with around XXXX female and XXXX male cases in 2016 in the United States.

Market Outlook

Market analysis carried out for the period of 2016-2027 demonstrates that the Market size of Myasthenia Gravis was found out to be USD XXXX million in 2016 in 7MM, growing at a CAGR of XX% for the forecasted period (2018-2027). At present, the therapeutic market size of Myasthenia Gravis is mainly accounted by symptomatic treatment. Recently, the medication of Alexion Pharmaceuticals got approval for MG treatment in 2017. This monoclonal antibody (MAB) is used for preventing acetylcholine receptor antibodies from affecting muscle cells and is helpful for patients resistant to the other available therapies. With regard to this, many companies are investing in the MG's MAB market and are looking for treatment of patients other than AchR antibodies, such as MUSK antibodies, since there is no treatment for MUSK antibody positive patients in the market till now. Thus, rise in research and development activities with various pipeline companies shifting their focus for novel mechanism of action myasthenia therapies, the dynamics of Myasthenia Gravis market is anticipated to change during the forecasted period (2018-2027).

Emerging Drugs Analysis

The dynamics of Myasthenia Gravis market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2018-2027.
The report covers a descriptive overview of the Myasthenia Gravis, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Myasthenia Gravis and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Myasthenia Gravis are provided, along with assessment of the impact new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted. Myasthenia Gravis market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Myasthenia Gravis market.

Reasons to buy:

1. The report will help in developing business strategies by understanding trends shaping and driving the Myasthenia Gravis market.
2. To understand the future market competition in the Myasthenia Gravis market and Insight reviews of the key market drivers and barriers.
3. Identification of strong upcoming players in the Myasthenia Gravis market will help in devising strategies that will help in getting ahead of competitors.
4. In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.

Companies Covered:

3.Catalyst Pharmaceuticals

And many others……………

Table of contents

1. Key Insights
2. Myasthenia Gravis (MG) Market Overview at a Glance
3. Disease Overview: Myasthenia Gravis (AS)
4. Epidemiology and Patient Population
5. Country Wise-Epidemiology of Myasthenia Gravis
5.1. United States
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. United Kingdom
5.7. Japan
6. Current Treatment Practices
7. Unmet Needs
8. Marketed drugs
8.1. Key cross competition- Marketed drugs
8.2. Mestinon: Valeant Pharmaceuticals
8.3. Soliris: Alexion Pharmaceuticals
8.4. Prograf: Astellas Pharma
8.5. Venoglobulin IH: Mitsubishi Tanabe Pharma
9. Emerging Therapies
9.1. Key cross competition- Emerging Therapies
9.2. Rozanolixizumab: UCB Pharma
9.3. CFZ533: Novartis
9.4. Efgartigimod : Argenx
9.5. RA101495: Ra Pharmaceuticals
9.6. Firdapse: Catalyst Pharmaceuticals
9.7. Hizentra: CSL Behring
9.8. IGIV-C: Grifols Therapeutics
10. Myasthenia Gravis: 7 Major Market Analysis
11. Market Outlook by Country
11.1. The United States: Market Outlook
11.3. EU-5 Countries: Market Outlook
11.4. Germany
11.5. France
11.6. Italy
11.7. Spain
11.8. United Kingdom
11.9. Japan: Market Outlook
12. Market Drivers
13. Market Barriers
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

*** For detailed TOC request for sample pages.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.